文献速递肺外科心外重症与机械循环支持

COVID-19呼吸衰竭肺移植的中期结局:UNOS数据库分析

Mid-Term Outcomes for Lung Transplantation in for COVID-19 Respiratory Failure: An Analysis of the United Network for Organ Sharing Database.
PubMed 文献 · J Thorac Cardiovasc Surg · 2026-10-19

本研究基于UNOS数据库2020至2024年数据,回顾性分析因COVID-19相关ARDS(CARDS)、COVID后肺纤维化(CPF)及非COVID限制性肺病(NCRLD)接受肺移植的成人受者。结果显示,COVID后受者术后ECMO、机械通气>48小时、新透析及急性排斥发生率更高,但无移植物衰竭生存率在IPTW调整后3年内与NCRLD相当。

要点

  • COVID后肺移植受者围术期并发症和资源利用更高,但中期生存与NCRLD相当。
  • 术后ECMO率22.6% vs 10.3%,通气>48小时67.5% vs 43.3%。
  • 需长期随访评估慢性移植物功能障碍。

核心结论

  • COVID后肺损伤肺移植虽围术期并发症和资源利用更高,但短期和中期生存结局与NCRLD相当。

研究设计与样本

  • 回顾性分析UNOS数据库2020至2024年成人肺移植受者,比较CARDS(256例)、CPF(338例)和NCRLD(8071例),采用IPTW和多因素logistic回归校正混杂因素。

主要发现

  • COVID后受者更年轻(54 vs 64岁,p<0.001),术前护理需求更高。
  • COVID后受者术后ECMO率22.6% vs 10.3%(p<0.001),通气>48小时67.5% vs 43.3%(p<0.001)。
  • COVID后受者新透析率11.0% vs 7.9%(p=0.012),急性排斥率7.7% vs 5.5%(p=0.026)。
  • IPTW调整后无移植物衰竭生存率3年内相当(Hochberg校正p=0.118)。

临床怎么用

  • COVID后肺移植受者围术期需更积极资源准备,但中期生存可接受。

局限性

  • 需长期研究评估慢性肺移植物功能障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lung transplantation is a feasible therapeutic option for irreversible lung injury caused by COVID-19, but comprehensive mid-term outcome data remain limited. This study evaluated outcomes after lung transplantation for COVID-19 acute respiratory distress syndrome (CARDS) and post-COVID pulmonary fibrosis (CPF) using a national registry. METHODS: We performed a retrospective analysis of the United Network for Organ Sharing database from 2020 through 2024. Recipient characteristics, perioperative complications, and graft failure-free survival were analyzed in adult lung transplant recipients with a primary diagnosis of CARDS, CPF, or non-COVID restrictive lung disease (NCRLD). Inverse probability of treatment weighting (IPTW) and multivariate logistic regression were performed to adjust for potential confounders. RESULTS: During the study period, 256 transplants were performed for CARDS, 338 for CPF, and 8071 for NCRLD. Post-COVID-19 recipients were younger (54 vs. 64 years, p<0.001) and required a higher level of care preoperatively than NCRLD recipients. Posttransplant, post-COVID-19 recipients experienced higher rates of posttransplant ECMO (22.6% vs. 10.3%, p<0.001), ventilation >48 hours (67.5% vs. 43.3%, p<0.001), new dialysis (11.0% vs. 7.9%, p=0.012), and acute rejection (7.7% vs. 5.5%, p=0.026). Graft failure-free survival was equivalent throughout the first year posttransplant between the post-COVID-19 and NCRLD recipients and, after IPTW for age and other confounders, was equivalent for up to 3 years (Hochberg-adjusted p=0.118). CONCLUSIONS: Lung transplantation for post-COVID-19 lung damage yields comparable short-term and mid-term survival outcomes despite higher perioperative morbidity and resource utilization. Long-term studies are needed to assess chronic lung allograft dysfunction in this population.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Hassaballa AS, O'Neill JW, Gregorio PHP, et al. Mid-Term Outcomes for Lung Transplantation in for COVID-19 Respiratory Failure: An Analysis of the United Network for Organ Sharing Database. J Thorac Cardiovasc Surg. 2026. PMID: 42896671. doi:10.1016/j.jtcvs.2026.09.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。